Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
EXEL vs. REGN: Which Stock Is the Better Value Option?
12:46pm, Wednesday, 06'th Mar 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks offers value investo
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
04:09pm, Monday, 04'th Mar 2024
If you're looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ: IBB ) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S.
Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
05:20am, Saturday, 10'th Feb 2024
Regeneron Pharmaceuticals reported strong Q4/2023 earnings, exceeding expectations and showing impressive growth from Dupixent and Libtayo. The company's next generation of blockbuster drugs are offse
EXEL or REGN: Which Is the Better Value Stock Right Now?
12:41pm, Thursday, 08'th Feb 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for t
Regeneron Announces Investor Conference Presentations
04:05pm, Tuesday, 06'th Feb 2024
TARRYTOWN, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Stock-Split Watch: Could These 2 Market-Beaters Be Next?
06:45am, Tuesday, 06'th Feb 2024
MercadoLibre's shares are trading at more than $1,000, while Regeneron's are getting close to that price. Neither company has ever conducted a stock split.
Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline
03:11pm, Friday, 02'nd Feb 2024
Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.
Regeneron's Push Into Obesity, Q4 2023 Earnings Review
12:43pm, Friday, 02'nd Feb 2024
Regeneron returned to topline growth in 2023 and this has led to the company's valuation rising to my expected EV/revenue range. The company is making significant investments in the obesity space, foc
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Call Transcript
11:59am, Friday, 02'nd Feb 2024
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Call Transcript
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say
10:31am, Friday, 02'nd Feb 2024
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall St
Regeneron (REGN) Q4 Earnings and Revenues Top Estimates
08:46am, Friday, 02'nd Feb 2024
Regeneron (REGN) came out with quarterly earnings of $11.86 per share, beating the Zacks Consensus Estimate of $10.43 per share. This compares to earnings of $12.56 per share a year ago.
3 Top Pharma Stocks to Buy Now: February 2024
05:00pm, Thursday, 01'st Feb 2024
Looking for pharma stocks to buy in February 2024? The pharmaceutical industry has always drawn a big crowd of investors.
Gear Up for Regeneron (REGN) Q4 Earnings: Wall Street Estimates for Key Metrics
10:21am, Tuesday, 30'th Jan 2024
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the
5 U.S. Corporate Giants to Buy on Solid Economic Data
09:26am, Monday, 29'th Jan 2024
We have narrowed our search to five U.S. corporate giants that have strong potential for 2024. These are: NFLX, PGR, BK, ANET, REGN.
Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline
11:06am, Friday, 26'th Jan 2024
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
